Peritoneal Carcinomatosis Clinical Trials 2023

What are the top hospitals conducting peritoneal carcinomatosis research?

Peritoneal carcinomatosis, a condition characterized by the spread of cancer cells to the lining of the abdominal cavity, demands innovative approaches and dedicated research. In Houston's M D Anderson Cancer Center, an esteemed institution renowned for its expertise in oncology, researchers are currently conducting 10 active peritoneal carcinomatosis trials. With a commendable track record of 24 completed trials since their first recorded investigation in 2005, this center leads the way in advancing our understanding and treatment options for this challenging disease.

The National Institutes of Health Clinical Center located in Bethesda is another prominent player in peritoneal carcinomatosis research. Despite having fewer ongoing trials compared to other institutions on this list with four active studies, they have made significant contributions over time with six previous investigations dating back to their initiation into peritoneal carcinomatosis trials also during 2005.

Out on the west coast, Kaiser Permanente Los Angeles Medical Center joins forces with four current peritoneal carcinomatosis clinical trials as part of their commitment to fighting against this devastating condition. Their dedication extends further through eight past investigations that have paved the way for progress since they embarked upon exploring potential solutions more than two decades ago—specifically from1992.

Venturing inland to Tucson's University of Arizona Cancer Center-North Campus reveals another hub for cutting-edge research. With four ongoing peritoneal carcinomatosis studies and seven accomplished trial initiatives since commencing exploration into this area during2009; these ardent researchers contribute significantly towards improving treatment outcomes for patients diagnosed with this formidable disease.

Rounding out our list is Providence Saint Joseph Medical Center/Disney Family Cancer Center situated in Burbank—a hospital not only associated with entertainment but also dedicated to making strides against cancer through dedicated clinical research efforts. Although they too encompass four active peritoneal carcinoma clinical experiments presently underway; interestingly enough theirs stretch beyond shorter span reaching up until ten years earlier when they initiated their earliest peritoneal carcinomatosis trial in 1992.

These leading hospitals, scattered across the United States, represent beacons of hope for patients battling peritoneal carcinomatosis. Their unwavering commitment to research and clinical trials is propelling us closer to breakthroughs that can improve outcomes and quality of life for those affected by this challenging condition.

Which are the best cities for peritoneal carcinomatosis clinical trials?

When it comes to peritoneal carcinomatosis clinical trials, several cities in the United States are at the forefront of research and innovation. Denver, Colorado leads with 20 active trials exploring treatments like Paclitaxel, Quality-of-Life Assessment, and SGN-B7H4V. Houston, Texas closely follows with 18 ongoing studies focused on Adavosertib, Paclitaxel, and Chemotherapy interventions. Anchorage, Alaska is also a notable city with 16 active trials investigating Letrozole, Quality-of-Life Assessment, and Paclitaxel as potential treatment options. Additionally, Tucson in Arizona has 14 active trials studying Paclitaxel and Letrozole among other interventions. Lastly Sacramento in California offers 13 active trials examining treatments such as Paclitaxel, Letrozole,and Oregovomab for peritoneal carcinomatosis patients. These cities provide valuable opportunities for individuals seeking participation in cutting-edge clinical research that may lead to improved outcomes against this challenging condition.

Which are the top treatments for peritoneal carcinomatosis being explored in clinical trials?

Peritoneal carcinomatosis, a challenging condition to treat, has seen notable advancements in clinical trials for various treatments. Paclitaxel emerges as a frontrunner with six active trials and an impressive 40 all-time studies dedicated to peritoneal carcinomatosis since its introduction in 2002. Close behind is cisplatin, currently being explored in three ongoing trials and having recorded 16 total peritoneal carcinomatosis studies since 2009. Additionally, pharmacological studies are gaining traction with two active trials and five overall research endeavors dating back to 2011. Quality-of-life assessment also enters the picture with two active trials and a portfolio of 20 past investigations starting from as early as 2005. Finally, chemotherapy shows promise through two current clinical trials alongside five historical studies beginning in 2012—a testament to the tireless efforts towards improving outcomes for patients battling peritoneal carcinomatosis

What are the most recent clinical trials for peritoneal carcinomatosis?

Exciting developments are occurring in the field of peritoneal carcinomatosis treatment, with recent clinical trials offering new hope for patients. The mEPIC trial, a Phase 2 study, explores innovative approaches to combat this condition and became available on 7/1/2023. Additionally, another trial investigates the potential benefits of combining IP FT538 and Enoblituzumab in treating peritoneal carcinomatosis—a Phase 1 study that became available on 4/28/2023. Furthermore, a compelling experimental approach involving chemotherapy combined with BEV and IMNN-001 is being evaluated through both Phase 1 and Phase 2 trials since becoming available on 2/10/2023. These groundbreaking studies pave the way towards enhanced treatments for peritoneal carcinomatosis patients who can now anticipate improved outcomes in their battle against this challenging disease.

What peritoneal carcinomatosis clinical trials were recently completed?

Recently completed clinical trials for peritoneal carcinomatosis have made significant strides in the search for improved treatments. In November 2021, OncoNano Medicine successfully concluded a trial investigating pegsitacianine as a potential therapy. Additionally, research led by Dan Blazer III, M.D., yielded insights into the effectiveness of Talimogene Laherparepvec, with their trial wrapping up in May 2019. These studies build upon earlier investigations such as Atezolizumab and Rucaparib trials sponsored by Hoffmann-La Roche and Clovis Oncology respectively (both completed in March 2017), along with Hyperthermic Intraperitoneal Chemotherapy (completed in September 2016) conducted at M.D. Anderson Cancer Center, Oxaliplatin research supported by University of Massachusetts Worcester (completed July 2016), and Adavosertib study sponsored by AstraZeneca (concluded January 2015). Collectively these endeavors highlight the ongoing commitment to advancing treatment options for patients grappling with peritoneal carcinomatosis.